THE OFFICIAL NEWS SOURCE OF ACR CONVERGENCE 2022 • NOVEMBER 10-14



Kristin D’Silva, MD: Rituximab for patients with interstitial pneumonia with autoimmune features

Kristin D'Silva, MD
Kristin D’Silva, MD

Poster presenter: Kristin D’Silva, MD, research fellow, Rheumatology Unit, Massachusetts General Hospital

Poster title: Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers

Scheduled poster session day and time: Sunday, Nov. 8, 9 – 11 a.m. EST

Visit the Poster Hall

What is your poster about?

We examined outcomes after initiation of rituximab in patients with interstitial pneumonia with autoimmune features (IPAF) at Mass General Brigham and University of Chicago. Fifty patients were included in the case series. We found that 40 (80%) patients were clinically improved or stable at one year after rituximab initiation, although only 21 (42%) were able to completely taper off corticosteroids. Nine patients experienced infections during treatment, and two patients discontinued treatment due to infections.

What makes this research important?

The optimal treatment strategy for IPAF is unknown.

What are you working on next related to this poster?

Randomized controlled trials are needed to determine the risks, benefits, safety, and cost-effectiveness of rituximab as a treatment for IPAF.